BioCentury
ARTICLE | Politics, Policy & Law

Carrots & sticks

Trump ‘bargain’ would trade tax, regulatory reforms for drug price negotiation

March 17, 2017 9:17 PM UTC

President Trump’s comments on drug prices, regulatory reforms and tax policy all seem to add up to an attempt to make an offer too good for the pharmaceutical industry to refuse.

The implicit deal appears to be that the administration and Congress would put in place a set of tax, regulatory and trade policies that benefit pharma companies, and in exchange biopharma companies would have to live with lower drug prices, especially for Medicare and Medicaid. ...